What is Livagen 20MG

Livagen 20MG is a synthetic tetrapeptide bioregulator studied in research for its targeted ability to rejuvenate liver tissue, modulate the immune system, and regulate chromatin structure in aging DNA. It is intended exclusively for research use.

Regarding its chemical identity, Livagen has a molecular formula of C18H35N7O9 and a molecular weight of 493.5 g/mol. Its reported canonical sequence is Lys-Glu-Asp-Ala. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include Livagen.

Product for research use.

Mechanism of action of Livagen

Livagen acts directly on the chromatin of lymphocytes and hepatocytes. It triggers the decondensation (unwinding) of chromatin in aging cells, which reactivates silenced genes responsible for ribosomal gene expression, protein synthesis, and cellular repair.

Pharmacokinetics and pharmacodynamics of Livagen

As a short Khavinson peptide, Livagen exerts its effects almost immediately upon entering the nucleus, initiating an epigenetic reset. The peptide itself is rapidly degraded into constituent amino acids, leaving a long-lasting regulatory effect.

Scientific evidence on Livagen

The available evidence on Livagen is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in models of acute and chronic liver damage, immunosenescence, and general aging. Preclinical evidence suggests it restores the functional capacity of aging T-cells and accelerates the regeneration of damaged liver parenchyma.

Livagen applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

Livagen protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for Livagen, so no trial schemes or quantities are specified.

The presentations of this product (20MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of Livagen

As a general guideline for laboratory handling, lyophilized peptides such as Livagen are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 20MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

Livagen Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented Livagen security profile

The documented safety information in open sources for Livagen is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Its action as an epigenetic normalizer presents a generally favorable theoretical safety profile in preclinical models. However, the exact long-term implications of chromatin decondensation in vivo are complex and remain unverified in comprehensive human trials.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

Livagen in a comparative context

Livagen is closely related to Epitalon in its mechanism of epigenetic regulation (chromatin decondensation), but its specific tropism is directed toward the liver and immune system rather than the pineal gland and telomerase.

History and development of Livagen

Synthesized by Russian researchers analyzing the specific short peptide sequences responsible for the regenerative properties of natural liver extracts. It was developed to combat age-related decline in hepatic and immune function.